RTKs are implicated in adaptive responses to BRAFi/MEKi treatment.7,14,31,32 By RPPA analysis, PDGFR-β and ErbB3 were upregulated in BRAF-mutant human melanoma cell lines, A375, 1205Lu, and M238 treated with BRAFi/MEKi for 24 h (Fig. 1a). This evidence concerns the gene PDGFRB and melanoma.